The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula: ##STR00001##

This invention relates to the new use of neurokinin-1(NK-1) receptor antagonists for treating sepsis, septic shock, systemic inflammatory response syndrome (SIRS), acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS). The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists and combinations with one or more therapeutic agents, for such uses.

Disclosed are compounds of Formula (I): or a salt thereof, wherein Q is: or; and X, R.sub.1a, R.sub.1b, R.sub.3, R.sub.4, and R.sub.5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

##STR00001##

Disclosed are compounds of Formula (I): or a salt thereof, wherein Q is: or; and X, R.sub.1a, R.sub.1b, R.sub.3, R.sub.4, and R.sub.5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

##STR00001##

The present invention concerns novel crystalline forms of {5-(4-bromo-phenyl)-6 [2 (5 bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as endothelin receptor antagonists. It also relates to new uses of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, either alone or in combination with other active ingredients or therapeutic agents.

The present invention concerns novel crystalline forms of {5-(4-bromo-phenyl)-6 [2 (5 bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as endothelin receptor antagonists. It also relates to new uses of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, either alone or in combination with other active ingredients or therapeutic agents.

Disclosed are compounds for medical uses, for example, compounds of formula Ia, ##STR00001##
wherein A.sub.1, A.sub.2, A.sub.3, A.sub.4, A.sub.5, A.sub.6, A.sub.7, R.sub.6, R.sub.7 and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

Disclosed is an oral sustained-release composition for an insoluble drug, which is especially suitable for a low-dose insoluble drug, the oral sustained-release composition comprises a sustained-release granule part and a gel skeleton part, the sustained-release granule part comprises the insoluble drug, an enteric material, and a strong liquid sorbent, and the gel skeleton part comprises a hydrophilic gel skeleton material; and the sustained-release granules are obtained by preparing the insoluble drug and the enteric material into a suspension and then spraying the suspension onto the strong liquid sorbent, the sustained-release granules are wrapped by the gel skeleton to form a multiple sustained-release system technology, which prolongs a release time, and has a simple preparation process, high efficiency, uniform drug mixing, and less content loss.

The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D.sub.4 receptor agonist.

The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D.sub.4 receptor agonist.